NA
MNPR icon

NewEdge Advisors’s Monopar Therapeutics MNPR Stock Holding History

NewEdge Advisors’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.9K Hold
600
– – ﹤0.01% 3047
2025
Q4 		$39.2K Hold
600
– – ﹤0.01% 3030
2025
Q3 		$49K Hold
600
– – ﹤0.01% 2831
2025
Q2 		$21.5K Hold
600
– – ﹤0.01% 2933
2025
Q1 		$21.8K Hold
600
– – ﹤0.01% 2834
2024
Q4 		$13.2K Hold
600
– – ﹤0.01% 2938
2024
Q3 		$4.04K Hold
600
– – ﹤0.01% 3215
2024
Q2 		$2.19K Hold
600
– – ﹤0.01% 3318
2024
Q1 		$2.04K Buy
+600
New +$1.79K ﹤0.01% 3363

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NewEdge Advisors's MNPR Position: Q1 2026 in Review

NewEdge Advisors held its Monopar Therapeutics (MNPR) position steady in Q1 2026 at 600 shares worth $32.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3047.

NewEdge Advisors first reported a position in MNPR in Q1 2024 and has held it in 9 quarters since. The position peaked at $49K in Q3 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • NewEdge Advisors held 600 shares of Monopar Therapeutics worth $32.9K as of Q1 2026.
  • NewEdge Advisors left its Monopar Therapeutics share count unchanged in Q1 2026.
  • Monopar Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #3047 holding.
  • NewEdge Advisors first reported a position in Monopar Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • NewEdge Advisors's Monopar Therapeutics position peaked at $49K in Q3 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.